TRU - Approval in Mexico to Enter Public Health Sector

Wednesday 7th February 2024

TruScreen receives Approval in Mexico to enter public health sector

Highlights

• TruScreen received Cofepris approval in Mexico, a major milestone and endorsement of the TruScreen technology

• Cofepris is Mexico’s national regulator and the approval grants TruScreen access to the country’s public health sector.

Truscreen Group Limited (NZX/ASX:TRU) is pleased to announce that the national regulator of Mexico, Cofepris has approved TruScreen access to the public health sector.

The approval allows TruScreen to expand its cervical cancer screening, currently, in the private health clinics to the wider public health sector. A 2020 census identified that only 2.3% of the population have private healthcare while 70.9% of the population accessed the public health system. Mexico has an addressable market of 65 million women.

HPVcentre.net estimated that 9,400 women are diagnosed annually with cervical cancer with a mortality rate of 46% - 4,300 deaths. Cervical cancer is the second most prevalent cancer amongst women in Mexico.

The CEO, Dr Beata Edling commented:

“The Cofepris approval highlights the accelerating acceptance of the TruScreen technology globally. I am delighted that women in Mexico will have access to faster, more efficient, and reliable cervical cancer screening with TruScreen. We congratulate our partner, Sunbird on achieving this significant milestone and look forward to advancing cervical cancer screening in Mexico”.

This announcement has been approved by the Board.

Ends

TruScreen Receives Approval in Mexico to Enter Public Health Sector

Comments from our readers

No comments yet